Bemnifosbuvir - Atea Pharmaceuticals
Alternative Names: AT-511-hemisulfate salt; AT-527 free base; AT‐527; RG-6422; RO 7496998Latest Information Update: 11 Jun 2024
At a glance
- Originator Atea Pharmaceuticals
- Class Amines; Antivirals; Esters; Fluorinated hydrocarbons; Phosphorus compounds; Purine nucleotides; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Hepatitis C
Most Recent Events
- 05 Jun 2024 Updated efficacy data from the phase II trial in Hepatitis C released by Atea Pharmaceuticals
- 21 May 2024 Atea Pharmaceuticals has patent protection for bemnifosbuvir worldwide
- 30 Apr 2024 Efficacy and pharmacokinetics data from a phase I trial in healthy volunteers released by Atea Pharmaceuticals